Gene-Editing Therapy Helps Nashville Sickle Cell Patients | City Limits

In early December, CRISPR-Cas9 gene editing therapy was approved by the Food and Drug Administration for the treatment of sickle cell in patients ages 12 and up. It’s the first FDA approval for the gene-editing therapy, whose creators won the Nobel Prize in chemistry in 2020.

Related Keywords

United States , American , Alyssa Weddle , Haydar Frangoul , Drug Administration , Cellular Therapy Program At Tristar Centennial , Tristar Centennial , Nobel Prize , Sarah Cannon Pediatric Transplant , Cellular Therapy Program , African American , Sickle Cell Disease , Sickle Cell , Health Care , Gene Editing ,